Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 2;25(11):2584–2595. doi: 10.1681/ASN.2013080896

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 by the American Society of Nephrology

PMC Copyright notice

Figure 5. — Sall1 is an activator in nephron progenitors and a repressor in differentiating nephrons. (A) Venn diagrams of the left show the overlap of decreased (upper panels) or increased (lower panels) probes in Six2GFPCre;Sall1^flox/flox kidneys and Sall1^CreER/flox kidneys 24 and 48 hours after tamoxifen treatment. The circle graphs on the right show the distributions of the decreased or increased genes in Six2-GFP–positive or -negative cells. Gene numbers are smaller than probe numbers because of the overlaps of the probes. KO, knockout. (B and C) Immunostaining for Cited1. Tamoxifen was injected at E12.5 and analyzed at E14.5. The expression of Cited1 is significantly decreased in the Sall1^CreER/flox kidney. Scale bar, 100 μm. (D and E) In situ hybridization of Osr1. The expression of Osr1 is mildly reduced in the Sall1^CreER/flox kidney at E14.5. (F–I) Immunostaining for Nkx6.1. The expression of Nkx6.1 in the differentiating nephrons (arrows) is significantly increased in both the Sall1^CreER/flox kidney treated with tamoxifen and the Six2Cre;Sall1^flox/flox kidney at E14.5.